IDH2 and myelodysplastic syndrome: Phase 2 trials investigate the combination of azacitidine and enasidenib in newly diagnosed and recurrent or refractory IDH2-mutated AML (NCT02677922, NCT03683433) [108], as well as in IDH2-mutated MDS (NCT03383575).